Inhibikase Therapeutics (NASDAQ:IKT) Upgraded at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded shares of Inhibikase Therapeutics (NASDAQ:IKT) to a strong-buy rating in a research note issued to investors on Wednesday,Zacks.com reports.

Several other equities analysts also recently weighed in on IKT. Cantor Fitzgerald raised Inhibikase Therapeutics to a “strong-buy” rating in a research note on Thursday, December 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research report on Thursday, January 22nd. Zacks Research raised Inhibikase Therapeutics to a “hold” rating in a report on Tuesday, December 2nd. Wall Street Zen raised Inhibikase Therapeutics to a “sell” rating in a research note on Saturday, December 27th. Finally, Lifesci Capital upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a research report on Monday, February 23rd. Four equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Inhibikase Therapeutics has an average rating of “Buy”.

Inhibikase Therapeutics Stock Performance

IKT stock opened at $1.88 on Wednesday. The firm’s 50 day moving average is $1.78. Inhibikase Therapeutics has a 12-month low of $1.33 and a 12-month high of $2.58. The firm has a market cap of $141.34 million, a P/E ratio of -4.82 and a beta of 0.76.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.